Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of HRS-7058 combined with antitumor therapy in solid tumors
CTR20252341Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7058, SHR-1826, SHR-9839 in Nonhematologic neoplasms, sponsored by Shandong Sende. Started Jul 2025; status: active.
02
Drugs
HRS-7058SHR-1826SHR-9839
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252341.